Cargando…
Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valen...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385862/ https://www.ncbi.nlm.nih.gov/pubmed/37515017 http://dx.doi.org/10.3390/vaccines11071201 |
_version_ | 1785081517026836480 |
---|---|
author | Haggenburg, Sabine Garcia Garrido, Hannah M. Kant, Iris M. J. Van der Straaten, Hanneke M. De Boer, Fransien Kersting, Sabina Issa, Djamila Te Raa, Doreen Visser, Hein P. J. Kater, Arnon P. Goorhuis, Abraham De Heer, Koen |
author_facet | Haggenburg, Sabine Garcia Garrido, Hannah M. Kant, Iris M. J. Van der Straaten, Hanneke M. De Boer, Fransien Kersting, Sabina Issa, Djamila Te Raa, Doreen Visser, Hein P. J. Kater, Arnon P. Goorhuis, Abraham De Heer, Koen |
author_sort | Haggenburg, Sabine |
collection | PubMed |
description | Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23). Because both CLL as well as immunosuppressive treatment have been identified as major determinants of immunogenicity, we aimed to assess the vaccination schedule in untreated and treated CLL patients. We quantified pneumococcal IgG concentrations against five serotypes shared across both vaccines, and against four serotypes unique to PPSV23, before and eight weeks after vaccination. In this retrospective cohort study, we included 143 CLL patients, either treated (n = 38) or naive to treatment (n = 105). While antibody concentrations increased significantly after vaccination, the overall serologic response was low (10.5%), defined as a ≥4-fold antibody increase against ≥70% of the measured serotypes, and significantly influenced by treatment status and prior lymphocyte number. The serologic protection rate, defined as an antibody concentration of ≥1.3 µg/mL for ≥70% of serotypes, was 13% in untreated and 3% in treated CLL patients. Future research should focus on vaccine regimens with a higher immunogenic potential, such as multi-dose schedules with higher-valent T cell dependent conjugated vaccines. |
format | Online Article Text |
id | pubmed-10385862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103858622023-07-30 Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia Haggenburg, Sabine Garcia Garrido, Hannah M. Kant, Iris M. J. Van der Straaten, Hanneke M. De Boer, Fransien Kersting, Sabina Issa, Djamila Te Raa, Doreen Visser, Hein P. J. Kater, Arnon P. Goorhuis, Abraham De Heer, Koen Vaccines (Basel) Article Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23). Because both CLL as well as immunosuppressive treatment have been identified as major determinants of immunogenicity, we aimed to assess the vaccination schedule in untreated and treated CLL patients. We quantified pneumococcal IgG concentrations against five serotypes shared across both vaccines, and against four serotypes unique to PPSV23, before and eight weeks after vaccination. In this retrospective cohort study, we included 143 CLL patients, either treated (n = 38) or naive to treatment (n = 105). While antibody concentrations increased significantly after vaccination, the overall serologic response was low (10.5%), defined as a ≥4-fold antibody increase against ≥70% of the measured serotypes, and significantly influenced by treatment status and prior lymphocyte number. The serologic protection rate, defined as an antibody concentration of ≥1.3 µg/mL for ≥70% of serotypes, was 13% in untreated and 3% in treated CLL patients. Future research should focus on vaccine regimens with a higher immunogenic potential, such as multi-dose schedules with higher-valent T cell dependent conjugated vaccines. MDPI 2023-07-04 /pmc/articles/PMC10385862/ /pubmed/37515017 http://dx.doi.org/10.3390/vaccines11071201 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Haggenburg, Sabine Garcia Garrido, Hannah M. Kant, Iris M. J. Van der Straaten, Hanneke M. De Boer, Fransien Kersting, Sabina Issa, Djamila Te Raa, Doreen Visser, Hein P. J. Kater, Arnon P. Goorhuis, Abraham De Heer, Koen Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia |
title | Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia |
title_full | Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia |
title_fullStr | Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia |
title_full_unstemmed | Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia |
title_short | Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia |
title_sort | immunogenicity of the 13-valent pneumococcal conjugated vaccine followed by the 23-valent polysaccharide vaccine in chronic lymphocytic leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385862/ https://www.ncbi.nlm.nih.gov/pubmed/37515017 http://dx.doi.org/10.3390/vaccines11071201 |
work_keys_str_mv | AT haggenburgsabine immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT garciagarridohannahm immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT kantirismj immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT vanderstraatenhannekem immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT deboerfransien immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT kerstingsabina immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT issadjamila immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT teraadoreen immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT visserheinpj immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT katerarnonp immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT goorhuisabraham immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia AT deheerkoen immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia |